Slide 1: Exchange filing cover letter: Investor Presentation
Biocon Biocon Limited 20th KM Hosur Road Electronics City Bangalore 560 100, india T9180 2808 2808 F91 80 2852 3423 CIN : L24234KA1978PLC003417 June 8, 2020 www.biocon.com To To The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Phiroze
Slide 2: Biocon Limited Investor Presentation June 2020
Biocon Limited BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM INVESTOR PRESENTATION June 2020 1
Slide 3: Safe Harbor
Safe Harbor Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.
Slide 4: Committed to Affordable Access
Committed to Affordable Access Aiming to develop products that can potentially benefit a billion patients 3
Slide 5: The Biocon Journey: A Continuous Evolution
The Biocon Journey: A Continuous Evolution 1978- 2000- 2005- 2010- 2016- 2019 & 1999 2004 2009 2015 2018 Beyond An Transforming Building the Base Strategic Global Commercialized Poised for Enzymes into a Business and Alliance with Biosimilars for Global Impact Company Biopharma Expertise in Mylan fo
Slide 6: Financial Highlights
FINANCIAL HIGHLIGHTS 5
Slide 7: Biocon's response to COVID-19
Biocon’s response to COVID-19 Invoked business continuity plans and implemented full employee protection measures Various initiatives undertaken to ensure running of essential and critical manufacturing and quality operations enabling us to serve our patients and partners Leveraged IT solutions and
Slide 8: Financial Summary
Financial Summary All Figures in ₹ Million except % Growth Particulars Q4 FY20 Q4 FY19 Growth FY20 FY19 (%) Revenue 16,441 15,570 6% 65,286 56,588 15% EBITDA 3,817 4,312 -11% 17,645 15,381 15% Net Profit# 1,234 2,137 -42% 7,600 7,291 4% R&D Expenses in 1,250 921 36% 4,394 2,899 52% P&L Gross R&D Spe
Slide 9: Revenue Highlights
Revenue Highlights All Figures in ₹ Million except % Particulars by segment Q4 FY20 Q4 FY19 Growth FY20 FY19 Growth - Small Molecules 5,407 4,719 15% 20,937 17,728 18% - Biologics 3,574 4,511 -21% 19,513 15,169 29% - Branded Formulations 1,172 1,330 -12% 5,362 6,564 -18% - Syngene (Research Services
Slide 10: Key Financial Metrics
Key Financial Metrics All Figures in ₹ Million except % FY19 FY 20 Particulars Q4 FY19 Q1 Q2 Q3 Q4 FY20 SEGMENT REVENUE a. Small Molecules 4,719 17,728 4,796 5,296 5,438 5,407 20,937 b. Biologics 4,511 15,169 4,896 5,161 5,882 3,574 19,513 c. Branded Formulations 1,330 6,564 1,334 1,283 1,573 1,172
Slide 11: Business Segments
BUSINESS SEGMENTS 10
Slide 12: Our Growth Verticals
Our Growth Verticals Biosimilars Small Molecules Branded Formulations Differentiated APIs & Generic GROWTH Finished Dosage Formulations Business in India & VERTICALS Overseas Novel Biologics Research Services 11
Slide 13: Small Molecules: APIs & Generic Formulations
Small Molecules APIs & Generic Formulations Differentiated API Portfolio Current Constituents Product Portfolio leverages core Portfolio fermentation technology strengths Simvastatin, Pravastatin, Atorvastatin, Statins Among world’s largest manufacturers of Rosuvastatin, & Fluvastatin. statins & imm
Slide 14: Biologics: Biosimilars & Novel Biologics
Biologics Biosimilars & Novel Biologics Novel Biologics Biosimilars Positioned among early Creating market leadership wave of entrants with in Innovation e.g., Insulin multiple biosimilars Tregopil, Itolizumab commercialized globally. 15+ years of experience is developing biologics. Pipeline include
Slide 15: Biocon Biologics: The Four Pillars
Biocon Biologics Transforming Healthcare, Transforming Lives Vision: “Most Inspiring Global Leader in Biologics” delivering affordable access to innovative and inclusive healthcare solutions, transforming patient lives. Implement strategic initiatives going beyond the product in our aspiration to re
Slide 16: Biocon Biologics Global Product Portfolio
Biocon Biologics Global Product Portfolio PIPLELINE OF 28 M O L E C U L E S BIOCON BIOLOGICS is independently developing many biosimilar assets With MYLAN, 11 biosimilars being co- developed for global markets With SANDOZ, set of next-gen immunology, oncology biosimilars being co-developed for globa
Slide 17: Biocon – Mylan Partnered Product Pipeline
Biocon – Mylan Partnered Product Pipeline Early mover in first wave of biosimilar launches in the next 3–5 years THERAPEUTIC STATUS MOLECULE AREA US EU MoW Launched in Australia, Canada & Emerging Trastuzumab Markets. Biocon’s strong development & Pegfilgrastim Launched in Canada and Australia manuf
Slide 18: Biocon - Sandoz exclusive partnership
Biocon - Sandoz exclusive partnership: Co-development of next-generation biosimilars Shared responsibility for… Broader Biocon Biologics’ participation in end-to-end Development development and commercialization Manufacturing Global regulatory approvals Various assets are in early stage development
Slide 19: Biocon Biologics: Manufacturing
Biocon Biologics: Manufacturing Global scale, cost competitive, complex manufacturing Global Scale Manufacturing Capabilities in India State-of-the-art manufacturing facilities – mammalian & microbial Facilities conform to most stringent cGMP guidelines Regulatory Approvals - EMA, US FDA, Health Can
Slide 20: Branded Formulations
Branded Formulations Folded under Biocon Biologics and aligned to new growth strategy Specialty business with regional ambitions; strong value builder for Biocon Biologics-led specialty products focused on chronic therapy areas. Comprehensive offering of products, patient and physician support progr
Slide 21: Novel Molecules
Novel Molecules Focused on Diabetes, Inflammation & Immuno-oncology Insulin Tregopil (In-house program) India Phase II in T2D First-in-Class Oral, Prandial Insulin completed. • Liver specific- portal delivery, Weight neutral DIABETES • Pivotal Phase II/III clinical study in T2DM patients in India on
Slide 22: Research Services (Syngene)
Research Services (Syngene) A global CRO company delivering innovative scientific solutions. Offering integrated research, development and manufacturing services for both small and large molecules, antibody-drug conjugates and oligonucleotides backed by best-in-class bioinformatics services Combinin
Slide 23: Questions
Questions INVESTOR RELATIONS CONTACT: Saurabh Paliwal Tel : +91 80 6775 2040 Email: investor.relations@biocon.com 22